

GENOMIC HEALTH INC  
Form 4  
October 05, 2005

**FORM 4**

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
ROBERTSON REBECCA B

(Last) (First) (Middle)

3000 SAND HILL ROAD, BUILDING 4 SUITE 210

(Street)

MENLO PARK, CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

GENOMIC HEALTH INC [GHDX]

3. Date of Earliest Transaction (Month/Day/Year)

10/04/2005

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_\_ Director  10% Owner  
\_\_\_\_ Officer (give title below) \_\_\_\_ Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	V	Amount	(A) or (D)	Price		
Common Stock	10/04/2005		C		36,036	A	\$ 0 36,036 <sup>(1)</sup>	I	By Versant Affiliates Fund I-A, L.P. <sup>(6)</sup>
Common Stock	10/04/2005		C		4,728	A	\$ 0 40,764 <sup>(1)</sup>	I	By Versant Affiliates Fund I-A, L.P. <sup>(6)</sup>
Common Stock	10/04/2005		J		1,648 <sup>(2)</sup>	A	\$ 0 <sup>(2)</sup> 42,412 <sup>(1)</sup>	I	By Versant

Edgar Filing: GENOMIC HEALTH INC - Form 4

Common Stock	10/04/2005	C	75,675	A	\$ 0	75,675 <sup>(1)</sup>	I	Affiliates Fund I-A, L.P. <sup>(6)</sup> By Versant Affiliates Fund I-B, L.P. <sup>(7)</sup>
Common Stock	10/04/2005	C	9,929	A	\$ 0	85,604 <sup>(1)</sup>	I	By Versant Affiliates Fund I-B, L.P. <sup>(7)</sup>
Common Stock	10/04/2005	J	3,462 <sup>(3)</sup>	A	\$ 0 <sup>(3)</sup>	89,066 <sup>(1)</sup>	I	By Versant Affiliates Fund I-B, L.P. <sup>(7)</sup>
Common Stock	10/04/2005	C	32,432	A	\$ 0	32,432 <sup>(1)</sup>	I	By Versant Affiliates Side Fund I, L.P. <sup>(8)</sup>
Common Stock	10/04/2005	C	8,890	A	\$ 0	41,323 <sup>(1)</sup>	I	By Versant Affiliates Side Fund I, L.P. <sup>(8)</sup>
Common Stock	10/04/2005	J	1,671 <sup>(4)</sup>	A	\$ 0 <sup>(4)</sup>	42,994 <sup>(1)</sup>	I	By Versant Affiliates Side Fund I, L.P. <sup>(8)</sup>
Common Stock	10/04/2005	C	1,657,657	A	\$ 0	1,657,657 <sup>(1)</sup>	I	Versant Venture Capital I, L.P. <sup>(8)</sup>
Common Stock	10/04/2005	C	449,265	A	\$ 0	2,106,923 <sup>(1)</sup>	I	By Versant Venture Capital I, L.P. <sup>(9)</sup>
Common Stock	10/04/2005	J	85,227 <sup>(5)</sup>	A	\$ 0 <sup>(5)</sup>	2,192,150 <sup>(1)</sup>	I	By Versant Venture Capital I,

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
					Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Preferred Stock	<u>(10)</u>	10/04/2005		C		108,108	<u>(11)</u>	<u>(12)</u>	Common Stock	36,036
Series E Preferred Stock	<u>(10)</u>	10/04/2005		C		14,184	<u>(11)</u>	<u>(12)</u>	Common Stock	4,728
Series B Preferred Stock	<u>(10)</u>	10/04/2005		C		227,027	<u>(11)</u>	<u>(12)</u>	Common Stock	75,675
Series E Preferred Stock	<u>(10)</u>	10/04/2005		C		29,787	<u>(11)</u>	<u>(12)</u>	Common Stock	9,929
Series B Preferred Stock	<u>(10)</u>	10/04/2005		C		97,297	<u>(11)</u>	<u>(12)</u>	Common Stock	32,432
Series E Preferred Stock	<u>(10)</u>	10/04/2005		C		26,672	<u>(11)</u>	<u>(12)</u>	Common Stock	8,890



## Edgar Filing: GENOMIC HEALTH INC - Form 4

- (10) Every 3 shares of Preferred Stock were converted into 1 share of Common Stock upon consummation of the IPO. This conversion rate is reflected in the amount of securities underlying the derivative security reported in column 7.
- (11) These securities are exercisable immediately.
- (12) These securities do not have an expiration date.

### Remarks:

General Remarks: This report is being filed jointly with the report filed by Versant Venture Capital I, L.P., Versant Affiliates I-A, L.P., Versant Affiliates Fund I-B, L.P., Versant Side Fund I, L.P., Versant Ventures I, LLC, Brian G. Atwood, Ross A. Ja M.D., William J. Link, Barbara N. Lubash and Donald B. Milder as of the date hereof and relates to the same transaction, namely automatic conversion of preferred stock held by the Reporting Persons upon consummation of the Issuer's initial public offering. Form 4 is being filed separately because the number of joint filers exceeded the maximum number of filers permitted by the EDGAR system on one form.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.